One of the largest-ever studies on the topic of deprescribing medications shows the potential promise, and pitfalls, of a massive effort to reduce overuse of a common class of heartburn medications known as proton pump inhibitors or PPIs. It also reveals that some of the feared risks from PPIs may be overblown.
In the drive to deprescribe, heartburn drug study teaches key lessons
- Post author:
- Post published:April 11, 2024
- Post category:News Feed
- Post comments:0 Comments